Prime Medicine pegs Sept 30 cash at ~$61.2M preliminary, excluding $13.7M restricted

Prime Medicine, Inc.

Preliminary unaudited cash, cash equivalents and short-term investments of approximately $61.2 million as of September 30, 2026; restricted cash of ~$13.7 million excluded.
Company has not completed its quarter-end close for Q3 2026; warns actual results may differ materially from these management estimates.
PricewaterhouseCoopers has not audited, reviewed, examined or compiled the preliminary figures and expresses no assurance on them.
Complete results will be reported in the Form 10-Q for the quarter ended September 30, 2026; no duty to update the estimates.
Updated November 2026 corporate presentation posted to the investor site; the Exhibit 99.1 text supplied here is truncated, so deck contents could not be verified.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.